文献速递药物相互作用抗栓抗凝管理药物不良反应与药物警戒

药代动力学相互作用药物与直接口服抗凝药疗效和安全性的关联:巢式病例对照研究

Association Between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study.
PubMed 文献 · Clin Pharmacol Ther · 2021-08-10

在Clalit队列中纳入89284例房颤和静脉血栓栓塞患者、126302患者年随访,采用巢式病例对照设计,发现P-gp/CYP3A4抑制剂与达比加群或利伐沙班联用增加严重出血风险,而苯妥英、卡马西平、丙戊酸或左乙拉西坦与DOAC联用增加房颤患者卒中/系统栓塞风险。

要点

  • 达比加群-维拉帕米、利伐沙班-维拉帕米、利伐沙班-胺碘酮联用与严重出血风险升高相关。
  • 苯妥英、卡马西平、丙戊酸或左乙拉西坦与DOAC联用与房颤患者卒中/系统栓塞风险升高相关。
  • 临床应关注DOAC与P-gp/CYP3A4抑制剂或诱导剂的潜在相互作用。

核心结论

  • 达比加群或利伐沙班与维拉帕米联用、利伐沙班与胺碘酮联用与严重出血风险增加相关。
  • 房颤患者DOAC与苯妥英、卡马西平、丙戊酸或左乙拉西坦联用与卒中/系统栓塞风险增加相关。

研究设计与样本

  • 在Clalit队列中设计巢式病例对照研究,纳入2010年1月1日至2020年8月24日新使用DOAC的房颤和静脉血栓栓塞患者。
  • 共纳入89284例房颤和静脉血栓栓塞患者,126302患者年随访。
  • 采用倾向性评分匹配,按年龄、性别、随访时长、入组年份、DOAC类型和适应症匹配最多20名对照。

主要发现

  • 严重出血事件1587例,达比加群-维拉帕米联用 adjusted OR 2.29 (1.13-4.60)。
  • 利伐沙班-维拉帕米联用 adjusted OR 2.18 (1.07-4.40),利伐沙班-胺碘酮联用 adjusted OR 1.68 (1.14-2.49)。
  • 房颤患者中卒中/系统栓塞事件1116例(79302例患者,118124患者年随访),苯妥英、卡马西平、丙戊酸或左乙拉西坦联用 adjusted OR 2.18 (1.55-3.10)。
  • 复发性静脉血栓栓塞风险因病例数少未能评估。

临床怎么用

  • 处方DOAC时应评估患者是否同时使用维拉帕米、胺碘酮等P-gp/CYP3A4抑制剂,警惕出血风险。
  • 房颤患者使用DOAC时应避免或谨慎联用苯妥英、卡马西平、丙戊酸或左乙拉西坦,以降低卒中/系统栓塞风险。

局限性

  • 复发性静脉血栓栓塞风险因病例数少未能评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Concomitant use of direct oral anticoagulants (DOACs) and medications with inhibition/induction effect on P-gp/CYP3A might increase risk of bleeding/treatment failure, respectively. We designed a nested case-control study within a Clalit cohort of patients with atrial fibrillation (AF) and a cohort of patients with venous thromboembolism, new users of a DOAC (January 1, 2010 to August 24, 2020). Propensity scores were constructed from demographic/clinical characteristics, and medications at cohort entry. Each case of: (i) serious bleeding event; (ii) stroke/systemic emboli (SE) in patients with AF; (iii) recurrent thromboembolism in patients with thromboembolism, was matched by age, sex, length of follow-up, year of cohort entry, DOAC type, and DOAC indication, to up to 20 controls. Within 89,284 patients with AF and venous thromboembolism and 126,302 patient-years of follow-up, there were 1,587 serious bleeding events. Risk of serious bleeding increased in association with concurrent prescription of P-gp/CYP3A4 inhibitors. Specifically, higher bleeding risk was associated with dabigatran-verapamil, rivaroxaban-verapamil, and rivaroxaban-amiodarone concurrent prescriptions: adjusted odds ratios (ORs) 2.29 (1.13-4.60), 2.18 (1.07-4.40), and 1.68 (1.14-2.49), respectively. There were 1,116 events of stroke/SE, in 79,302 DOAC-treated patients with AF and 118,124 patient-years of follow-up. Concomitant use of phenytoin, carbamazepine, valproic acid, or levetiracetam was associated with risk for stroke/SE: adjusted OR 2.18 (1.55-3.10). Risk of recurrent venous thromboembolism could not be assessed due to the low number of cases. Concurrent prescriptions of dabigatran or rivaroxaban with verapamil, and of rivaroxaban with amiodarone, are associated with increased risk for serious bleeding. Higher risk for stroke/SE in patients with AF is associated with concurrent prescriptions of DOACs with phenytoin, carbamazepine, valproic acid, or levetiracetam.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Gronich N, Stein N, Muszkat M, et al. Association Between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study. Clin Pharmacol Ther. 2021. PMID: 34287842. doi:10.1002/cpt.2369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。